Research Article
Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain
Table 5
Effectiveness and mean cost-effectiveness (MCER) for Sequences a, b, c, d over 2 years.
| | Expected number of days in RS | Expected number of days in LDAS | MCER (estimated mean cost per day in RS) | MCER (estimated mean cost per day in LDAS) |
| | Sequence A: ETA-ABA-ADA | 52 | 102 | 846 € | 427 € | | Sequence B: ETA-RTX-ADA | 33 | 82 | 1,301 € | 508 € | | Sequence C: ETA-ADA-ABA | 22 | 64 | 2,489 € | 729 € | | Sequence D: ETA-ADA-INF | 10 | 32 | 4,568 € | 1,352 € |
|
|
RS: remission.
LDAS: low disease activity state.
MCER: mean cost-effectiveness ratio.
|
